Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 5/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | TK1 | P04183 | 2/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TK2 | O00142 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13646172 | 0.90 | RNASE1 (0.46) | RNASE1DNMT1ADRB1TK1ALB | |
| SCHEMBL14773848 | 0.90 | RNASE1 (0.46) | RNASE1DNMT1ADRB1TK1ALB | |
| SCHEMBL12015121 | 0.90 | ALB (0.38) | RNASE1DNMT1ADRB1TK1ALB | |
| SCHEMBL12087580 | 0.90 | ALB (0.38) | RNASE1DNMT1ADRB1TK1ALB | |
| SCHEMBL67563 | 0.90 | ALB (0.38) | RNASE1DNMT1ADRB1TK1ALB | |
| SCHEMBL10331938 | 0.89 | RNASE1 (0.45) | RNASE1DNMT1ADRB1TK1DNMT3B | |
| SCHEMBL21423131 | 0.89 | RNASE1 (0.45) | RNASE1DNMT1ADRB1TK1ALB | |
| SCHEMBL6517103 | 0.89 | RNASE1 (0.45) | RNASE1DNMT1ADRB1TK1DNMT3B | |
| SCHEMBL68514 | 0.89 | DNMT1 (0.36) | RNASE1DNMT1ADRB1TK1ALB | |
| SCHEMBL18573362 | 0.89 | DNMT1 (0.36) | RNASE1DNMT1ADRB1TK1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
| WO-2022125987-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | MAPT, GAP43, RNMT | RNASE1 2030/4885DNMT1 1507/4885ADRB1 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.